Treatment of neuropathic pain by Haanpää, Maija
L Ä Ä K E I N F O R M A A T I O T A  L Ä Ä K E L A I T O K S E L T A
LÄKEMEDELSINFORMATION FRÅN LÄKEMEDELSVERKET, FINLAND  |  DRUG INFORMATION FROM THE NATIONAL AGENCY FOR MEDICINES, FINLAND 
3 . 2 0 0 3
S a m m a n d r a g
Ledare
Hannes Wahlroos  . . . . . . . . . . . . . . . . . . . . .
Maija Haanpää  . . . . . . . . . . . . . . . . . . . . . . .
Biverkningar
Marja-Leena Nurminen | Jyrki Vanakoski | 
Leena Sommarberg | Erkki Palva  . . . . . . . . . . . . .
Ulla Närhi  . . . . . . . . . . . . . . . . . . . . . . . . . . .
Medicintekniska produkter
Hely Reinikka-Railo | Kirsti Kotaniemi  . . . . .
S u m m a r y
Editorial
Hannes Wahlroos  . . . . . . . . . . . . . . . . . . . . .
Maija Haanpää  . . . . . . . . . . . . . . . . . . . . . . .
ADR News
Marja-Leena Nurminen | Jyrki Vanakoski | 
Leena Sommarberg | Erkki Palva  . . . . . . . . . . . . .
Ulla Närhi  . . . . . . . . . . . . . . . . . . . . . . . . . . .
32
33
37
41
42
43
45
46
50
53
54
Överraskande problem med läkemedelstillgänglighet
Läkemedelsbehandling av neuropatisk smärta
Uppföljning av biverkningar 30 år i Finland
Försiktighetsåtgärder gällande användningen av 
telitromycin för patienter med Myasthenia gravis
En fråga om klassificering
Nya bestämmelser och rekommendationer för bröstimplantat
inom EU-området
The surprising problem of unavailable medicines
Treatment of neuropathic pain
Thirty years of adverse drug reaction monitoring in Finland
Classification issue
Lääkelaitoksen päätöksiä
3.2003
11. vuosikerta
11 årgången
11th Annual volume
TABU 3.2003 45
On the eve of Finland’s EU membership eight and a half
years ago, no one would have believed that one of the
results of becoming a member would be the unavailabil-
ity of medicines. Nevertheless, this is now the case.
Medicines are  authorised for the market through
quicker and more efficient marketing authorisation
processes. Nonetheless, medicines do not necessarily
make their way to the pharmacy shelves or to the cus-
tomers. Naturally, the patients and all of health care
suffer the consequences, but it also signifies a waste of
expert resources and administrative idling.
Still in 1993, all the authorised medicines were, prac-
tically speaking, available on the market. In those days,
the Medicines Act required that a medicinal preparation
had to be placed on the market within a year of market-
ing authorisation being granted. Failing this, the autho-
risation expired. The price of the medicinal preparation
was negotiated to a reasonable level already by the time
the authorisation was granted.
In  May 2003, there were 4,700 nationally granted
marketing authorisations in force in Finland. Only 77
per cent of these products were placed on the market in
Finland. As of 1995, 700 marketing authorisations have
been issued centrally in the EU, but even fewer of these
– only about 40% – are available in Finland. It is also
extraordinary that pharmaceutical companies, more of-
ten than before, apply first to the Finnish National
Agency for Medicines for marketing authorisation, us-
ing Finland as a so-called Reference Member State, but
of the medicinal products concerned (about 260 market-
ing authorisations, mainly for generic preparations) only
a fifth have been placed on our market. 
The availability problem affects all kinds of medi-
cines. As examples we could mention the hypertension
medicine (irbesartan + hydrochlorothiazide) that re-
ceived marketing authorisation in 1998, the arrhythmia
medicine (dofetilide) that received marketing authorisa-
tion in 1999, and the implant (rhBMP-2) used in the
treatment of shinbone fractures that received marketing
authorisation in 2001, in addition to a host of generic
preparations. Whatever opinion one might have of the
therapeutic value of products on the ‘haven’t got’ list,
the current situation is not acceptable. What is the point
of maintaining an administratively demanding advance-
control system of a high level of expertise and efficiency,
if products do not, in fact, come into use?
There are, to be sure, many reasons for the situation
that has arisen. They may be related to the small size of
the Finnish market and the consequent profitability esti-
mates. Every product placed on our market must have
the appropriate packaging and patient information
leaflet  in Finnish and Swedish. Apart from that, the
reason may be – at least from the pharmaceutical indus-
try’s point of view – the problem related to the pricing
negotiations for purposes of admittance into the drug
reimbursement system in general, and to a special reim-
bursement category in particular. The problem is exacer-
bated by there being insufficient obligations or incen-
tives to place medicines on the market. Current ‘desir-
ability paragraphs’ of the Medicines Act do not appear
to suffice. It is true that the EU’s medical legislation re-
view package contains a recommendation for obligatory
placement of medicines on the market, but in a more le-
nient form than previously applicable in Finland.
The authorities do not have sufficient means to ac-
tively promote the placing of medicines on the market.
In any case, the causes of the problem should be stud-
ied. The Finns have the right to assume that medical in-
novations approved by the EU, or generic medicines ap-
proved by the Finnish National Agency for Medicines,
would be normally available here as well. 
Hannes Wahlroos
DIRECTOR GENERAL, PROFESSOR
National Agency for Medicines
The surprising problem of unavailable medicines
Editorial
Summary 
Translation Liisa Fellman-Paul
The definition, prevalence and
diagnosis of neuropathic pain
According to the definition of the
International Association for the
Study of Pain, neuropathic pain, i.e.
pain caused by damage to neural tis-
sue, is a pain condition caused by
damage to, or a functional disorder
in, the pain transmitting nerve sys-
tem (1). The term “neurogenic pain”
is used when the functional disorder
is reversible, as  distinct from a con-
dition of neuropathic pain, indicat-
ing a permanent abnormality. The
neuropathic pain conditions are dis-
tinguished according to the site of
the lesion: central or of CNS origin
(e.g. a pain condition following a
cerebrovascular accident), peripheral
or of peripheral nervous system ori-
gin (e.g. diabetic neuropathy, pain
after neural tissue damage), or a
combination of these (e.g. post-her-
petic neuralgia). 
It is estimated that about one
percent of the UK population suffers
from neuropathic pain conditions,
and it is therefore a rather common
complaint for which doctors need to
find appropriate treatment. About
8% of patients who have had a cere-
bral infarct, 28% of MS patients,
and a minimum of 50% of patients
with spinal cord injury suffer from
neuropathic pain. 
According to a Finnish study,
8% of patients with adult type dia-
betes have peripheral polyneuropa-
thy at the time of diagnosis, the
most common symptoms of which
in addition to pain are numbness
and lack of sensation (2). About 5%
of patients with peripheral nerve
damage develop pain caused by
neural tissue damage. Animal stud-
ies show that proneness to the devel-
opment of a condition of neuropath-
ic pain following peripheral nerve
damage is determined by hereditary
factors.
The diagnosis and treatment of
neuropathic pain are based on the
location of the pain and the logical
neuroanatomical localisation
through signs and symptoms indi-
cating abnormal function of the tac-
tile sense (e.g. in the region innervat-
ed by a nerve branch or root), and
the identification of the cause of the
damage. The symptoms may include
continuous pain, scintillating pain
resembling an electric shock, allody-
nia, i.e. a condition in which a nor-
mally painless stimulus is trans-
formed into pain, and various ab-
normal sensations such as paraesthe-
sia and dysaesthesia. The tactile
sense may be exaggerated or im-
paired depending on the quality of
the sensation. If the diagnosis is evi-
dent (post-herpetic neuralgia, for ex-
ample), no further examinations are
necessary following the taking of a
good past medical history and ex-
amination of the status of the pa-
tient. Depending on the individual
case, however, it may be advisable
to use imaging, laboratory and neu-
rophysiological examinations to es-
tablish the cause of the symptoms
and the options for treatment, de-
pending on the cause. In neuropath-
ic pain, however, it is only rarely
possible to deal with the cause, and
treatment is therefore symptomatic.
The mechanisms of neuropathic
pain have not yet been fully estab-
lished. The plasticity of the nervous
system, i.e. its ability to undergo
functional and structural changes in
association with various disease
processes, is a key issue in the devel-
opment of neuropathic pain condi-
tions. In conditions of peripheral
neuropathic pain, increased forma-
tion of impulses has been found in
the pain nerve ends, axons and sen-
sory ganglia. This is at least partly
due to the increased number of sodi-
um channels in the cell membrane of
the nerve. Another prominent char-
acteristic of neuropathic pain is the
relative weakness of central inhibito-
ry mechanisms. Sensitisation also
occurs at that level of the central
nervous system where the activation
of NMDA receptors plays a central
role. Drugs used for the treatment of
neuropathic pain have several differ-
ent mechanisms of action which are
logical in view of the pathophysio-
logical mechanisms (Table 1).
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Neuropathic pain, i.e. pain caused by damage to neural tissue, is traditionally considered a condi-
tion difficult to treat. Nevertheless, several drugs are available which have proven effective in con-
trolled clinical trials. The best medication for each patient is found through individual trials of var-
ious therapies. Tricyclic antidepressants, carbamazepine, gabapentin and tramadol may be tried in
primary health care. In complex situations it may be worthwhile considering referring the patient
to a pain clinic for treatment assessment.
Summary 
TABU 3.2003 47
Treatment of neuropathic pain
In some patients the symptoms may
be so mild as merely to need a diag-
nosis and an explanation of the
mechanisms of the symptoms and
the character of the pain. Neuro-
pathic pain is not a warning sign of
anything; instead, it is a nuisance
produced by a damaged sensory
path. Exacerbation of symptoms as
a result of various stimuli is not a
sign of further damage. The patient
is encouraged to avoid those situa-
tions which most exacerbate the
symptoms and to look for alterna-
tive courses of action, the aim being
activity and a good quality of life in
spite of the symptoms. If the pain
causes disruption to the patient’s
everyday life, it is justified to try
some medical treatment. According
to a meta-analysis, the alleviation of
pain can be considered good if a
30% reduction in neuropathic pain
is obtained or a minimum reduction
of two numbers in the scale of sever-
ity of pain from 0 to 10 (3). A mini-
mum of 50% pain relief, i.e. the cri-
terion used in the NNT (number
needed to treat) calculations, indi-
cates very good alleviation of pain
(3, 4).
The choice of medication de-
pends on the patient’s previous ex-
perience of drugs available on the
market, other diseases and associat-
ed medication, motivation to try the
suggested medication, the price of
the drug and the symptom picture.
If the most difficult symptom is a
scintillating pain resembling an elec-
tric shock, the first line of treatment
is carbamazepine. It is recommended
that hyperaesthesia following herpes
zoster in elderly patients with a mul-
titude of illnesses be treated with li-
docaine ointment as a first choice.
Dosage recommendations for each
drug are detailed in Table 2. If even
after a dose adjustment the efficacy
of the drug being tried is not suffi-
cient according to the patient’s own
judgment, the first drug is with-
drawn and replaced by another one
for the patient to test. After experi-
menting with some monotherapies,
combinations of drugs with various
mechanisms of action can be tried.
Complex polypharmacy ought, how-
ever, to be avoided.
Tricyclic antidepressants
Tricyclic antidepressants are the cor-
ner stone of neuropathic pain treat-
ment. Their efficacy is proven in
both central and peripheral neuro-
pathic pain conditions (4). Consider-
able differences in efficacy between
different drugs have not been found,
but notriptyline is better tolerated
than amitriptyline (5). Alleviation of
pain is independent of the effect of
the mood, its onset is more rapid
and relief can be attained at lower
doses. As the patient’s sleep is often
disturbed, the first effect to be de-
sired of the drug is undisturbed
sleep at night. The total benefit can
be assessed once the drug has been
used for a couple of weeks without
changing the level of the dosage.
Since the metabolism of tricyclic an-
tidepressants varies extensively be-
tween individuals, specifications for
concentrations are recommended if
the patient exhibits undesirable ef-
fects even at low doses, or if there is
no response at daily doses as high as
150 mg. While the concentration is
being monitored, the dose may be
increased by titration as necessary if
the drug is well tolerated by the pa-
tient. The most common undesirable
effects include tiredness, dryness of
the mouth, constipation, distur-
bances of micturition and orthostat-
ic hypotension. Weight problems,
disturbances of sexual functions and
arrhythmias may occur. The blood
dyscrasias are rare. To avoid seda-
tion the drug should be taken early
on in the evening before going to
bed. Dryness of the mouth can be
relieved by topical sialagogues, and
constipation can be treated by laxa-
tives which increase the bulk of the
intestinal contents. The patients
with narrow-angle glaucoma, pros-
tatic hyperplasia or heart disease
should be treated with caution. 
Antiepileptic agents
Carbamazepine is the drug of choice
in trigeminal neuralgia; it brings re-
lief to about 70% of the patients. It
has also been found effective in oth-
er conditions of neuropathic pain
(4). The same dosage regimes are
applied as in epilepsy, and the serum
drug concentration can be estab-
lished as necessary. Blood count and
liver values should be monitored, es-
pecially at the start of treatment.
The most common adverse reactions
include tiredness, vertigo and hy-
ponatraemia. Liver-enzyme-induced
interactions with many drugs, in-
cluding combined oral contracep-
tives, should be borne in mind. Car-
bamazepine and oxcarbazepine are
equally effective in trigeminal neu-
ralgia (6). Oxcarbazepine is better
tolerated than carbamazepine, but it
is recommended that the serum sodi-
um level be monitored at the begin-
ning of the treatment to exclude the
possibility of hyponatraemia.
Gabapentin is effective in the
treatment of pain caused by diabetic
neuropathy, post-herpetic neuralgia
and phantom pain (7-10). The ab-
sorption of gabapentin is saturating
and it has no pharmacokinetic inter-
actions with other drugs as it is not
metabolised in the liver but it is
completely excreted via the kidneys.
Due to its safety of use and efficacy,
along with tricyclic drugs gaba-
pentin is considered as first line
treatment in the neuropathic pain
conditions mentioned above.
Table 1 .   Mechanisms of  act ion of  drugs used for  the treatment of
neuropathic  pain.
Tricyclic antidepressants serotonin and noradrenaline effect
Carbamazepine sodium channel blockade
Oxcarbazepine sodium channel blockade
Tramadol serotonin and noradrenaline effect, 
µ−opioid agonism 
Gabapentin calcium channel blockade
Lamotrigine sodium channel blockade, 
inhibition of glutamate release
Oxycodone µ−opioid agonism 
Topical lidocaine sodium channel blockade at the 
nerve ends
Gabapentin is administered three
times a day, and the target dose in
the treatment of pain is 900–3,600
mg/day. The response to treatment
can be assessed within a couple of
days of reaching the target dose.
The most common adverse reactions
are vertigo, tiredness and oedema.
The efficacy of lamotrigine is
proven in conditions of both central
and peripheral pain (11-15). The
dose is increased very slowly to
avoid rash. Monitoring by laborato-
ry tests is not necessary, and adverse
reactions of CNS origin are fewer
than with conventional antiepileptic
agents. Due to the slow titration of
the dose, the use of lamotrigine is
restricted to the cases where drugs
with easier administration have not
brought adequate relief.
Opioids
The effect of tramadol is exerted via
both the opioid receptors and the
serotonin and noradrenaline sys-
tems. Tramadol, classified amongst
the weak opioids, causes distinctly
less dependence and tolerance than
strong opioids do. Its efficacy is
proven in conditions of polyneuro-
pathic pain and post-herpetic neu-
ralgia (16-18). The most common
adverse reactions include nausea,
vertigo, tiredness and headache. In-
teractions with antidepressants
should be kept in mind in the ad-
ministration of tramadol; serotonin
syndrome and elevated concentra-
tions are possible (19).
Pure opioids were previously
considered to have no effect on neu-
ropathic pain, but a proportion of
patients with neuropathic pain were
later shown to benefit from their
use. Oral oxycodone with long-term
effect is proven to be effective in
both post-herpetic neuralgia (20)
and conditions of diabetic neuro-
pathic pain (21). The doses used in
the studies were relatively small, 20-
80 mg/day. The most common ad-
verse reactions include tiredness,
constipation and pruritus. The sta-
tus of strong opioids in the treat-
ment of neuropathic pain remains
unsettled, since only a proportion of
patients benefit from these drugs
and because of the dependence
strong opioids may cause. As a rule,
introduction of strong opioid thera-
py for other than cancer pain is the
responsibility of special clinics. Be-
fore starting opioid therapy it is nec-
essary to know the patient, to be
truly familiar with the effects of opi-
oids, and to know how to carry out
the treatment and how to make a
correct selection of patients. The
dose is slowly increased by titration
and by monitoring the response and
any possible adverse reactions. The
use of a laxative which increases the
bulk of the intestinal content is rec-
ommended to be introduced at the
start of the opioid therapy. If signifi-
cant pain relief is not obtained by
the opioid, the drug is slowly with-
drawn by gradually decreasing the
dose.
Topical lidocaine
Topical lidocaine, both in gel and
plaster format, is found effective in
post-herpetic neuralgia if the patient
has dynamic mechanic allodynia, i.e.
light touching of the skin is painful.
The effect is based on the sedation
of overactive nerve end function
(22-23). In Finland, both the lido-
caine ointment and the lidocaine
plaster are preparations for compas-
sionate use. The ointment is applied
three times a day on to skin sensitive
to touch. The use of plaster for 12
hours a day provides an effect for
24 hours. 
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Table 2.   Administrat ion and dosage of  drugs for  neuropathic  pain
Drug Initial dosage Titration of dose Maximum recommended
daily dose*
Tricyclic antidepressants 10–25 mg at night 10–25 mg in increments 150 mg or according to
every 3–7 days concentration
Carbamazepine depotpreparation 100 mg x 2 100 mg in increments according to 
every 3–7 days concentration
Gabapentin 300 mg at night 300–900 mg in increments 3,600 mg*
every 1–3 days, taken 
3 times daily
Lamotrigine 25 mg x 1 25–50 mg in increments, 400 mg*
every 1–2 weeks,
taken twice daily
Tramadol 50 mg x 1 50 mg in increments, 400 mg
taken 3 times daily, 
depotpreparation 
twice daily
Oxycodone 10 mg x 2 10 mg in increments 80 mg*
every 1–3 days, 
taken twice daily
* the maximum dose used in studies on neuropathic pain
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Conclusion
Even though new appropriate drugs
have been introduced in recent years
for the medical treatment of neuro-
pathic pain, we are nowhere near
achieving reasonable control of pain
in all patients. Dorsal column stimu-
lation of the spinal cord may be use-
ful in these cases if one is dealing
with peripheral neuropathic pain.
On-going research in the field is ex-
tensive and novel preparations are
expected to figure on the market in
the near future. As knowledge of the
mechanisms of neuropathic pain be-
comes more specific, it will be possi-
ble to develop drugs based on the
newly found mechanisms of action.
In practical work it is worth bearing
in mind that the support shown by
the physician towards his/her patient
is especially important when the
benefit of medical treatment remains
modest. If a good response is ob-
tained, occasional appointments for
the evaluation of the condition and
renewal of the prescription are rec-
ommended as with the treatment of
any chronic disease
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The purpose of an ADR register is
to identify any new risks associated
with the use of drugs. The rarer the
adverse reactions, the better the reg-
ister works as a tool for their identi-
fication. The information made
available through the reports on
common adverse reactions is never-
theless difficult to interpret. Many
of the more common reactions also
occur in patients who have not even
received the drug, which often
makes it difficult to establish the ex-
tent of the effect of the drug exhibit-
ed in the reaction produced.
The reporting of adverse drug re-
actions is done on a voluntary basis
in Finland, whereas in Sweden and
Norway, for example, it is mandato-
ry to report any adverse reactions.
The mandatory reporting does not
necessarily improve the register, be-
cause voluntary reporting may pro-
duce reports better in quality rather
than a larger number of reports. Sig-
nificant under-reporting also occurs
in countries where it is mandatory
to report (1, 2). 
Despite the voluntary reporting
system in Finland, the National
Agency for Medicines hopes that all
suspected adverse reactions will be
reported. It is especially advised that
serious adverse reactions caused by
drugs, including fatalities, life
threatening reactions, reactions re-
quiring hospitalisation or prolonga-
tion of the hospital stay, reactions
causing continuous functional defect
or impairment of functional ability,
and reactions causing congenital
anomalies or abnormalities, should
be reported. It is also advised  to re-
port all drug interactions, including
adverse reactions to new medicinal
products which have been available
on the market for less than two
years, increased frequency of a sus-
pected adverse reaction and unex-
pected adverse reactions the charac-
ter and seriousness of which differ
from those listed in the SPC. It is
advisable to report even already
known adverse reactions. In this
context, it should be emphasised
that a mere suspicion of a possible
adverse reaction is sufficient reason
for submitting an ADR report.
ADR reports
The annual number of reports on
adverse drug reactions in recent
years has been around 700–800
(Fig. 1). The proportion of serious
reactions among these reports is
about 50%. This is nevertheless only
a fraction of the real number of sig-
nificant adverse reactions.
The most important groups of
drugs figuring in the reports include
antimicrobials, drugs affecting the
nervous system, and drugs for the
treatment of diseases of the cardio-
vascular system and of the musculo-
skeletal system (Table). One symp-
tom at least in about a quarter of
the ADR reports consisted of vari-
ous skin reactions; other common
symptoms of adverse reactions com-
prised various general symptoms,
adverse reactions of the blood
count, the gastrointestinal tract, the
respiratory organs and the nervous
system (Fig. 2).
Thirty years of adverse drug reaction monitoring
in Finland
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Fig.  1 .   The number of  ADR reports  in  F inland 1973–2002
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Report evaluation 
ADR reports submitted to the Na-
tional Agency for Medicines are
discussed on a weekly basis at ex-
pert meetings, where the evaluation
of causality in the submitted re-
ports and an assessment of the seri-
ousness are made. The majority of
the ADR reports contain informa-
tion given by a doctor to the
Agency about the reaction. The
marketing authorisation holder of
the drug receives a copy of the re-
port, without personal details of
the patient, on both serious and
non-serious reactions caused by the
drug. If the reporting doctor wishes
his/her details to remain confiden-
tial and their availability to be re-
stricted only to the National
Agency for Medicines, then the in-
formation given in the report is
sent to the marketing authorisation
holder anonymously without the
name or contact details of the doc-
tor. Doctors may also report to the
marketing authorisation holder di-
rectly who then, within 15 days of
the report, is required to report to
the National Agency for Medicines
all the serious adverse reactions
which have occurred in Finland. 
The reports on serious ADRs re-
ceived by the Agency are reported
to the EMEA, other EU member
states and the WHO database.
A large number of common ad-
verse reactions are detected early
on in the drug trials designed and
carried out for new drug develop-
ment and marketing authorisation
purposes. Prior to the approval of a
marketing authorisation, a new
drug has nevertheless only been
tested in a maximum of a couple of
thousand patients. Consequently,
rare adverse reactions which occur
in less than one in a thousand re-
cipients are often not detected in
these clinical studies. Experience of
the risks associated with long-term
treatment is also limited prior to
the approval of a marketing autho-
risation. It is nevertheless unreason-
able to require considerably more
extensive trials than at present for
the approval of a marketing autho-
risation, because they would delay
and prevent the development of
new and necessary drugs and they
could delay the most effective treat-
ment of diseases. Adverse reactions
with a smaller frequency than
1:10,000 may also be significant,
especially if they are caused by
drugs which are widely used. In
practice, the detection of this type
of rare adverse reactions will not
be possible until the drug has been
in general use for years. Patients in
potential risk groups are often fil-
tered out before clinical trials, but
after the approval of the marketing
authorisation the use of the drug is
often extended to these patient
groups as well. Reporting of ADRs
covers all drug consumers in need
of actual treatment, and this makes
the detection of adverse reactions
in the risk groups easier. For the
same reason, various problems as-
sociated with drug interactions are
often not detected until the drug is
actually used in a particular thera-
py.
A suspected association between
the drug therapy and symptoms
and findings constitutes an ade-
quate basis for making an ADR re-
port. It is important that indefinite
suspicions and unusual observa-
tions are also reported. In individ-
ual cases it is almost impossible to
demonstrate a causality relation-
ship. However, if independent ob-
servations are received from vari-
ous sources, it may reinforce the
suspicion of a new adverse reaction
caused by a drug.
The ADR register is a poor tool
for the quantitative evaluation of
ADRs because the reports received
are made on varying grounds and
represent an unknown proportion
of the ADRs occurring in real life.
According to studies, under-report-
ing is more common in association
with non-serious and familiar reac-
tions than with serious and unex-
Adverse react ions of  var ious drugs reported to the ADR Register  of  the
National  Agency for  Medicines during 1973–2002 (percentage of the report-
ed drugs)
Drugs for diseases of the gastrointestinal tract and for metabolic diseases 5%
Drugs intended for diseases of the blood and blood forming organs 2%
Drugs used in diseases of the cardiovascular system 17%
Dermatologicals 2%
Drugs aimed at diseases of the genito-urinary and sex hormone systems 5%
Hormonal preparations (excluding sex hormones) 1%
Anti-infectives 28%
Antineoplastic and immunomodulating agents 3%
Drugs for diseases of the musculoskeletal system 11%
Drugs affecting the nervous system 19%
Antiparasitic products, insecticides and repellents 1%
Drugs for diseases of the respiratory system 3%
Drugs for diseases of the sensory organs 1%
Other 2%
8,5 %
6,7 %
8,6 %
11,6 %
2,5 %
4,6 %
2,7 %6,9 %2,3 %
7,1 %
24,6 %
13,8 % Blood and lymphatic systemdisorders
Cardiac and vascular
disorders
Gastrointestinal disorders
General disorders and local
disorders
Hepatobiliary disorders
Investigations
Musculosketetal and
connective tissue
Nervous system disorders
Psychiatric disorders
Respiratory, thoracic and
mediastinal disorders
Skin and subcutaneous
tissue disorders
Other
Fig.  2.   The divis ion of  ADR reports  by organ groups during 1973–2002
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pected reactions (1, 2, 3), and, it is
consequently the detection of new
and serious signals which represents
the most important value of ADR
reports.
Comparisons of safety between
different drugs should be made espe-
cially carefully if they are based on
the information available in the
ADR register. The number of reports
on a particular drug varies over dif-
ferent periods of time, depending on
the extent to which the drug is used,
its novelty value, publicity and other
factors which are not associated
with the effect of drug. The number
of reports on adverse reactions
caused by a new drug during the
first years of marketing is multifari-
ous in comparison with that in sub-
sequent years. News in the mass me-
dia about adverse drug reactions
may also increase the reporting of
reactions.
The information available in the
ADR register cannot be considered
comprehensive as to its quantity and
quality, and, consequently, further
details are required to reinforce the
safety signals generated on the basis
of the information, for example, by
establishing the causality relation-
ship of the drug to the adverse reac-
tion and its frequency. 
Well-designed epidemiological
studies are one way of obtaining
further information. Such studies
can provide assessments of the oc-
currence of the adverse reaction and
comparative information on risks
between different drugs. Preclinical
studies can be used to establish the
mechanism by which any adverse re-
action is generated.
After the assessment, if any reac-
tion appears to be new and signifi-
cant, measures can be taken to pre-
vent any further adverse reactions.
These measures include, for exam-
ple, the inclusion of the reaction and
the associated warnings and precau-
tions in the product information (the
SPC and the PIL). Other measures
could include the stipulation of a re-
striction for use, e.g. changing the
OTC status of a drug to a prescrip-
tion only drug, or restricting the
therapeutic indications and user
groups of the drug. Information bul-
letins published on the website of
the National Agency for Medicines
(www.nam.fi), or health care profes-
sional (dear doctor) letters, can be
used for attracting the attention of
doctors. In extreme cases, the prod-
uct may be suspended, and the mar-
keting authorisation may be with-
drawn if necessary. The final discus-
sion of any significant measures as-
sociated with safety usually takes
place at the CPMP; its evaluation
then leads to a Commission decision
which is binding to all EU member
states.
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Summary 
A medicine is a preparation or a
substance the purpose of which,
when used either internally or exter-
nally, is to cure, alleviate or prevent
a disease or the symptoms of a dis-
ease in humans or animals. A prepa-
ration or a substance used either in-
ternally or externally to establish the
condition or the cause of a disease,
or to restore, improve or change the
physiological function in humans or
animals, is also considered to be a
medicine (Section 3 of the Medicines
Act).
The National Agency for Medi-
cines has published a list as a guide-
line on the substances which are to
be considered medicines
(http://www.nam.fi/english/laws/clas-
sification/medicine-list/index.html).
The substances listed in appendix 1
and the herbals listed in appendix 2
can be considered medicines. The
substances and herbals are listed in
alphabetical order in the list togeth-
er with their Latin, Finnish and
Swedish names.
Other substances and herbals
used in accordance with Section 3 of
the Medicines Act and with a medic-
inal purpose comparable to that of
substances listed in appendix 1 or
herbals listed in appendix 2 can also
be considered medicines. Prepara-
tions and substances used for medic-
inal purposes can also be classified
as medicines without regard to their
form, composition, manufacturing
method or mechanism of action,
which may be dissimilar to those of
conventional medicines. These in-
clude radioactive pharmaceutical
preparations, allergen preparations
and medicinal gases.
Preparations having daily doses
containing vitamins or minerals in
excess of the amounts indicated in
appendix 3 of the list of medicines
can also be classified as medicines.
Vitamin and mineral preparations
intended for children are considered
medicines.
The list of medicines is con-
firmed every three years. The list
was last confirmed in 2000, which
means that the next list of medicines
will be published this year.
Classification of medicines
According to the Medicines Act, it is
the responsibility of the National
Agency for Medicines to determine
whether a substance or a prepara-
tion should be considered a medi-
cine. The classification is established
for each product individually the
product being classified either as a
medicine, a non-medicine or a med-
ical device. The classification is de-
pendent on both the composition of
and the therapeutic use for the prod-
uct. The product is classified as a
medical device if it fulfils the criteria
defined in the legislation (Act on
Medical Devices 1505/1994).
Written request
A signed application for classifica-
tion is required for a product to be
classified (an application by e-mail is
not valid). The application for clas-
sification including enclosures
should contain the following details
• the name of the preparation
• precise qualitative and quanti-
tative composition
• proposed therapeutic use
• pictures of packages
• any information of classifica-
tion category in another coun-
try
The application for classification
should include full contact details of
the applicant in case any further in-
formation.
The decision on classification is
obtainable on payment of EUR 85
within about 1–2 months of submit-
ting the application. The decision
will be sent in writing to the appli-
cant.
After the decision 
Once the product is classified as a
medicine, it may not be sold as a
foodstuff or as a grocery item. A
marketing authorisation is subse-
quently applied for where a product
classified as a medicine. Information
on marketing authorisation applica-
tions is available on the website of
the NAM http://www.nam.fi/eng-
lish/control/marketing_authorisa-
tion/index.html. The manufacturer is
responsible for the sale and the
choice of an appropriate channel of
sale. It is the duty of the manufac-
turer also to ensure that a prepara-
tion classified to be sold at pharma-
cies is withdrawn from the shops
selling health food products. 
Guidelines on the marketing and
launching medical devices are to be
found on the website http://www.
nam.fi/english/devices/index.html
More information on website
Information on issues associated
with the classification of medicines
is available on the Agency’s website
http://www.nam.fi/english/laws/clas-
sification/index.html
The classification of a product
does not, however, mean that mar-
keting authorisation would have
been obtained for the product.
Classification issues
Translation Mervi Moisander
